Value Assessment Frameworks

There are many aspects to the U.S. health care system, as well as many different stakeholder viewpoints on how to address current challenges as our system shifts from one driven by the volume of health care services to one focused on the value of health care that is provided. As part of this shift and as a way to address health care costs, there is an increased interest in understanding how to assess the value of all aspects of health care.

Value assessments are a new and evolving area, and they have the potential to have a tremendous impact on patient treatment decisions, as well as on coverage and reimbursement decisions. In recent years, a number of organizations, such as the Institute for Clinical and Economic Review (ICER), Sloan Kettering Memorial Cancer Center (Drug Abacus) and the American Society for Clinical Oncologists (ASCO) have developed frameworks to assess new treatments.

While we recognize the importance of evaluating treatment costs, many of these frameworks fall short in their efforts to balance this evaluation with a comprehensive consideration of benefits to the patient. By not incorporating the full value and benefits of medical innovation, as well as the patient's input, frameworks will fall short of their goal to meaningfully assess value.

To keep patient concerns front and center, it’s important to assess the issue of value through a broader, patient-focused lens. Given the National Pharmaceutical Council’s role as a policy research organization with a commitment to ensuring the use of sound methodology, we developed “guiding practices for patient-centered value assessment” to help stakeholders comprehensively consider value with the patient in mind.

  • NPC's "Guiding Practices for Patient-Centered Value Assessment" establish good practices to guide meaningful value assessments. The Guiding Practices address the assessment process; methodology; benefits; costs; evidence; and dissemination and utilization, as well as considerations for budget impact assessment.
  • NPC's "Current Landscape: Value Assessment Frameworks" builds on Neumann and Cohen's informative comparison of frameworks by carrying the assessment further and providing specific detailed observations. It delves deeper into the rather disparate frameworks by comparing and contrasting key characteristics such as their intended purposes, development processes, methods, and the elements of value (benefits and costs).
  • NPC also has outlined concerns with the Institute for Clinical and Economic Review's (ICER) Value Assessment Framework in both comments and a letter to ICER President Dr. Steven Pearson. NPC cited the framework’s lack of model transparency, challenges with how the health system value is calculated, and the need to realize the effects of some treatments over a longer time horizon, among other concerns.
  • NPC submitted comments to the American Society of Clinical Oncology on the proposed “Framework to Assess the Value of Cancer Treatment Options,” intended to help patients and providers assess the relative value of cancer therapies. NPC’s comments focused on how to improve the patient-centricity of the framework to enhance its ultimate value as a shared decision-making tool. In particular, NPC recommended broadening the framework to include more factors that patients value, strengthening the assessments of clinical benefits and toxicity, ensuring cost information is relevant to patients, expanding the evidence base that underlies the framework, and safeguarding against framework misuse. 
Blog Post

NPC Value Conference Sparks Dialogue to Define, Understand Value in Health Care

How do we measure the value of a medical intervention, its benefits to patients, and the associated costs to patients, payers and society as a whole...
Blog Post

Putting Patients First® in the Value Equation: An Interview With the National Health Council’s Dr. Eleanor Perfetto

National Pharmaceutical Council President Dan Leonard caught up this week with Eleanor Perfetto, PhD, MS, Senior Vice President of Strategic...
Commentary and Testimony Page

Chain Drug Review – Commentary: "Considering Value in Health Care"

This commentary was originally published in the July 25, 2016, issue of Chain Drug Review.By: Dan Leonard, President, National Pharmaceutical...
Press Release

National Pharmaceutical Council to Host Conference on Measuring Health Care Value and Impact on Patient Care

(Washington, DC, September 15, 2016)—The National Pharmaceutical Council (NPC) will bring together health care stakeholders on September 29 for a...
Press Release

National Pharmaceutical Council to Host Conference on Measuring Health Care Value and Impact on Patient Care

(Washington, DC, September 15, 2016)—The National Pharmaceutical Council (NPC) will bring together health care stakeholders on September 29 for a...
Press Release

National Pharmaceutical Council Remains Engaged With the Institute for Clinical and Economic Review, Continuing Constructive Dialogue to Improve Value Assessment Frameworks

(Washington, DC, September 8, 2016)—The National Pharmaceutical Council (NPC) Board of Directors has agreed to renew the health policy research...
Press Release

NPC Takes Issue With ICER's Mischaracterization of Funding Sources

The National Pharmaceutical Council (NPC) takes exception to the Institute for Clinical and Economic Review’s (ICER) continued portrayal of us as an...
Commentary and Testimony Page

Chain Drug Review – Commentary: "Considering Value in Health Care"

This commentary was originally published in the July 25, 2016, issue of Chain Drug Review.By: Dan Leonard, President, National Pharmaceutical...
Commentary and Testimony Page

NPC Submits Comments to Institute for Clinical and Economic Review on Its Value Framework

September 12, 2016Steven D. Pearson, MD, MSc, FRCP President Institute for Clinical and Economic Review One State Street, Suite 1050 Boston, MA 02109...
Commentary and Testimony Page

Thinking Differently About How We Assess Health Value

Health care stakeholders remain divided over how the value of health care treatments—especially medicines—should be assessed, and whether existing...
Blog Post

NPC Value Conference Sparks Dialogue to Define, Understand Value in Health Care

How do we measure the value of a medical intervention, its benefits to patients, and the associated costs to patients, payers and society as a whole...
Blog Post

Putting Patients First® in the Value Equation: An Interview With the National Health Council’s Dr. Eleanor Perfetto

National Pharmaceutical Council President Dan Leonard caught up this week with Eleanor Perfetto, PhD, MS, Senior Vice President of Strategic...
Blog Post

NPC Submits Comments to Institute for Clinical and Economic Review on Its Value Assessment Framework

The National Pharmaceutical Council (NPC) today submitted comments to the Institute for Clinical and Economic Review (ICER) about ways to improve its...
Blog Post

Moving Value Frameworks from Fledgling to Functional

Defining value in health care – especially as our health system shifts its focus from rewarding the volume of services provided to rewarding the...
Current Landscape: Value Assessment Frameworks

Current Landscape: Value Assessment Frameworks

This paper builds on Neumann and Cohen's informative comparison of value assessment frameworks...